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GUIDELINES FOR THE PREVENTION 
AND CONTROL OF 
CONGENITAL SYPHILIS
1. Introduction
Congenital syphilis causes fetal or perinatal death in 40% of the infants affected. The 
condition was well described in the 15th century and has long been recognized as a distinct 
syndrome in which the source is an infected adult. Several theories have been advanced to 
explain how the infection is transmitted, including transmission from a father infected with 
syphilis and transmission from an infant’s nursing an infected wet nurse. Transplacental 
transmission from an asymptomatic infected mother was first described in 1906.
The availability of penicillin treatment for syphilis in pregnancy has not eradicated con­
genital syphilis. Since 1970, the incidence of congenital syphilis has closely reflected the 
incidence of primary and secondary syphilis in women. In 1986, more cases of congenital 
syphilis (365) were reported to the Division of Sexually Transmitted Diseases, Center for 
Prevention Services, CDC, than for any of the previous 15 years. That year almost one of every 
10,000 live-born infants in the United States had congenital syphilis. The proportion of 
stillbirths caused by syphilis is unknown.
In July 1987, CDC invited 10 consultants* to discuss the problem of congenital syphilis and 
to determine possible ways to solve the problem. This supplement to the Morbidity and 
Mortality Weekly Report (MMWR) presents guidelines that were developed from discussions 
with these consultants. Efforts were made to balance the ideal with the feasible, promoting a 
focused and coordinated source of guidance for health care providers. Although some 
aspects of the guidelines are based on limited data, the information provided here represents 
the best judgment of experts.
2. Surveillance
Congenital syphilis surveillance should be conducted at the local, state, and national levels. 
The provisional case definition includes every infant (person <12 months of age) with one of 
the following: 1) a reactive nontreponemal serologic test for syphilis confirmed by a reactive 
treponemal test, 2) a positive darkfield microscopic examination on a non-oral mucous 
membrane, or 3) a positive fluorescent antibody examination for Treponema pallidum on 
any lesion.
*The consultants were PJ Wiesner, MD, Chairperson (CDC), ER Alexander, MD (CDC), B Bernard, MD 
(University of South Carolina School of Medicine), J Hill (Florida Department of Health and Rehabilitative 
Services), D Hughes, MPH (Children’s Defense Fund), LV Klerman, DrPH (Yale University School of 
Medicine), M Norgard, PhD (University of Texas Health Science Center at Dallas), L Olsen, MD, MPH 
(Delaware Department of Health and Social Services), L Taber, MD (Baylor College of Medicine), and 
GD Wendel, MD (University of Texas Southwestern Medical School).
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Physicians, clinics, and hospitals should report all cases that meet the provisional definition 
to the local public health authority. Laboratories should report indicative findings to the same 
authority. All areas that have five or more women with early infectious syphilis (infection of <1 
year’s duration) per 100,000 population should establish an active surveillance system for 
congenital syphilis at key hospitals. At a minimum, hospitals in areas with a high incidence of 
syphilis or that serve patient populations known to be at increased risk for syphilis should 
perform routine serologic tests for syphilis (STS) using blood samples from the umbilical cord.
All cases that are classified as “confirmed” or “compatible” or that require additional 
information to be classified should be reported to the state public health authority (see 
definitions of case classifications below). These initial reports identify problem areas and 
ensure appropriate follow-up at the state level. Later, a Congenital Syphilis Follow-up Form, 
CDC 73.126, should be completed and forwarded through the local and state public health 
authorities to the Division of Sexually Transmitted Diseases, CDC, for all infants (including 
stillborns) who have not been classified as “unlikely.” Cases that cannot be classified with 
reasonable assurance (e.g., they are lost to follow-up) should also be described as fully as 
possible on the form CDC 73.126. The surveillance information documented on the form is 
used to determine why the particular case occurred and to identify trends. Completion of these 
forms enables investigators to measure the occurrence of congenital syphilis.
All forms CDC 73.126 should be completed by the time an infant reaches 8 months of age, 
including forms for cases lost to follow-up. For surveillance purposes, stillbirths also should be 
evaluated for syphilis, and those with a diagnosis consistent with congenital syphilis should be 
documented on the form CDC 73.126 through local and state public health authorities in the 
same manner as live births.
Diagnostic Classifications of Congenital Syphilis
Confirmed case
• identification of T. pallidum by darkfield microscopy, fluorescent antibody, or other specific 
stains in specimens from lesions, autopsy material, placenta, or umbilical cord
Compatible (formerly, “probable” or “possible”) case
• a reactive STS in a stillborn
OR
• a reactive STS in an infant whose mother had syphilis during pregnancy and was not 
adequately treated, regardless of symptoms in the infant
OR
• a reactive Venereal Disease Research Laboratory (VDRL) test of cerebrospinal fluid
OR
• a reactive STS in an infant with any of the following signs: snuffles, condyloma lata, 
osteitis, periostitis or osteochondritis, ascites, skin and mucous membrane lesions, 
hepatitis, hepatomegaly, splenomegaly, nephrosis, nephritis, or hemolytic anemia
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OR
• fourfold or greater rise in titers* or nontreponemal tests (VDRL or rapid plasma reagin 
[RPR] and a confirmed fluorescent treponemal antibody absorption (FTA-ABS) or micro­
hemagglutination assay for antibody to T. pallidum (MHA-TP) over a 3-month period
OR
• a reactive treponemal test or nontreponemal test that does not revert to nonreactive in 
6 months
Unlikely case
• no reactive STS
OR
• treponemal tests revert to nonreactive within 6 months
OR
• no symptoms in live-born infant whose mother, treated for syphilis during pregnancy, had a 
fourfold or greater fall in titer and the infant’s STS is also fourfold or lower than the maternal 
titer was at the time of treatment
Two other aspects of surveillance for congenital syphilis warrant emphasis. First, a sensitive 
system is needed by which state and local sexually transmitted diseases (STD) control 
programs are made aware of reactive STS. The programs should evaluate and follow indi­
vidual reactive serologic test reports and should monitor the reporting patterns of laboratories 
and diagnosticians. Furthermore, a quality assurance system is needed to confirm that all 
medical laboratories performing tests for STD are complying with official reporting regula­
tions. Compliance should be checked by letter, telephone, or personal visit at least every 
6 months.
Second, state health departments should maintain a central registry of patients who receive 
treatment for syphilis. Each patient’s record should include specific information about the 
stage of disease, the type(s) and amount(s) of medication administered, the types and results 
of laboratory tests, and, if the patient is pregnant, the trimester during which she is treated. 
This information is essential for the proper medical management of pregnant women, their 
fetuses, and their infants. Strict confidentiality and data security procedures must be estab­
lished, periodically reviewed, and independently tested to ensure that registry information is 
neither misused nor unintentionally revealed to unauthorized persons.
3, Control
The control of early infectious syphilis is essential for the control of congenital syphilis. 
When the prevalence of infectious syphilis substantially increases among reproductive-age 
women, cases of congenital syphilis very likely will follow. Increased prevalence has been 
observed in several areas of the United States in recent years. To prevent future cases of 
congenital syphilis, STD control programs need to place more emphasis on early syphilis 
control, especially in areas with a high incidence.
3.1 Disease Intervention Activities for Early Infectious Syphilis
The traditional “tools” of early syphilis control in the United States include an original
*“Fourfold rise in titer,” “fourfold fall in titer,” and other similar phrases are used throughout this document. 
They refer to changes (up or down) in serum titers of at least two dilutions (two “tubes”), e.g., from 1:2 to 1:8 
(and the reverse), or from 1:4 to 1:16 (and the reverse), or from 1:32 to 1:8 (and the reverse).
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interview of the patient to elicit information on sex partners, rapid notification of partners, 
selective reinterviews, and selected “clustering” around the patient and his/her examined sex 
partners to obtain information on other persons who may be at risk of infection. Recom­
mended techniques, methods, and procedures are discussed in the disease intervention 
courses sponsored by the Division of Sexually Transmitted Diseases.
3.2 Specific Activities for State and Local STD Control Programs for the 
Prevention of Congenital Syphilis
• Ensure that official public health statutes and/or regulations mandate STS on all pregnant 
women at the time of the initial prenatal visit and early in the third trimester.
• Monitor public and private laboratories regularly to ensure the prompt and thorough 
reporting of reactive STS.
• Assess the pregnancy status of women with diagnosed syphilis and of women who are the 
sex partners of men with diagnosed syphilis.
• Ask early infectious syphilis patients or their unexamined sex partners who reside in 
neighborhoods with a high incidence of syphilis to identify women in the area who may be 
pregnant. Refer all identified women for serologic testing and prenatal care.
• Inform every woman of reproductive age who is seen in an STD clinic (for any reason) 
about the need for prenatal care and STS in future pregnancies.
• Encourage prenatal screening for syphilis wherever pregnant women are seen for health 
care, including women, infants, and children (WIC) programs, methadone maintenance 
clinics, detention facilities, and prenatal care facilities; whenever possible, review existing 
clinic protocols and suggest specific amendments to the clinic medical director.
• Conduct selective serologic screening of women of childbearing age in groups with an 
increased risk of infection, e.g., women residing in neighborhoods that have a particularly 
high incidence of syphilis.
• Deliver educational messages to the medical community about laboratory tests, diag­
nostic criteria, treatment, and follow-up of patients who are at risk of infection and who may 
be pregnant.
• Develop and disseminate public service educational messages to women who share 
demographic characteristics with the women most often diagnosed with early syphilis. In 
many areas of the United States, these women are young, single, members of a minority 
group, and residents of a central city neighborhood. Brief, well-targeted radio announce­
ments in the language and vernacular of the audience may be particularly effective.
3.3 STD Program Priorities
Although no published studies have evaluated the benefit-to-cost ratio in controlling early 
syphilis by using the traditional method (see section 3.1) versus less laborious and time- 
consuming methods, the former has been a mainstay of most STD control programs in the 
United States for many years. The traditional syphilis-intervention process requires time, 
commitment, and human resources, and — like other public health strategies — it should be 
periodically assessed by state and local STD programs for its benefits and costs. In an era of 
increasing demands for public health resources, the relative effectiveness of the traditional 
process should be compared with that of less vigorous methods in areas of both high and low 
syphilis incidence.
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A thorough initial interview that includes obtaining information on the patient’s sex partners 
(names and addresses) usually takes at least 45 minutes. In areas with an increased 
incidence of syphilis, clinic procedures and flow patterns may need to be restructured to 
accommodate this essential time requirement.
3.4 O ther Considerations
The interrelationship of syphilis and human immunodeficiency virus (HIV) infection should 
be explored in areas with a high incidence of syphilis. HIV infection may influence the 
manifestation of syphilis or its response to therapy. The role, if any, of the genital ulcers of 
syphilis in increasing the risk of HIV transmission also needs study in U.S. population groups. 
State and local STD programs need to coordinate control resources for both syphilis and HIV, 
offer STS to all women requesting HIV tests, and perform periodic syphilis tests on all persons 
known to be HIV-antibody positive.
4. Prenatal Care
Comprehensive prenatal care started early in pregnancy is essential in preventing con­
genital syphilis. Unfortunately, many obstacles make it difficult for women, particularly some 
poor and some minority women, to obtain needed care. These obstacles include financial 
barriers, the limited availability of health care providers who are willing to serve these 
populations, provider difficulty in communicating with patients who are poor or from different 
ethnic backgrounds, organizational arrangements that minimize accessibility and accept­
ability of treatment, poor coordination of services, and patients’ inadequate understanding of 
the need for care. Any modifications of the present system that would reduce these obstacles 
would also improve the opportunities for women with syphilis to receive care.
Additional specific strategies are needed to encourage the use of prenatal care by women 
who may be at increased risk of transmitting syphilis to their fetus, to ensure that these women 
are adequately screened, and to maintain follow-up. These strategies include targeted out­
reach efforts, coordination of activities among service providers, and special prenatal care 
components.
4.1 STD Control Programs
STD control programs should institute special prenatal outreach programs for patients who 
are at risk for syphilis. All women of childbearing age who come to STD clinics should be 
asked the date of their last menstrual period. If they have not had a period in the previous 
6 weeks, and if their periods are usually regular, they should be tested for pregnancy as soon 
as possible, preferably on site. If on-site pregnancy testing is not available, STD clinic 
personnel should make an appointment for the patient at a facility that can do the testing with 
minimum delay. An RPR card test should be performed routinely on all patients at STD clinics; 
the laboratory forms of pregnant patients should be “flagged” for priority processing. All 
pregnant patients, regardless of the results of the RPR, should be referred for prenatal care. If 
the RPR test is reactive, however, arrangements should be made immediately to institute 
appropriate treatment, sex partner referral, and prenatal care. State and local STD programs 
should arrange with prenatal care providers to treat women with reactive syphilis tests as 
medical emergencies. Such women should be given the highest priority for prenatal care, 
particularly at clinics with waiting lists. If the woman reports normal menses, or the pregnancy
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test is negative, she should be informed about the availability of family planning services and 
about the potential hazards to a fetus caused by STD, cigarette smoking, alcohol, and drugs.
Patients with early infectious syphilis should be interviewed to identify their recent sexual 
partners. Women who are so identified should receive the highest priority for referral for 
treatment and, if pregnant, for enrollment in effective prenatal care. Patients with early 
infectious syphilis who live in high-incidence neighborhoods should also be asked to identify 
friends, associates, and family members who might be pregnant (see section 3.2). Outreach 
workers should contact these women, explain to them that syphilis is a potential problem in 
their community, offer them a test for syphilis, and assist them in enrolling in a prenatal care 
facility. Pregnant women with a reactive STS should receive the highest priority for treatment 
and prenatal care. STD program managers need to develop management systems that track 
and measure the outreach activities focused on pregnant patients and their prenatal care.
4.2 Drug Addiction Programs
All women of childbearing age who come to clinics for drug addiction should also be asked 
the date of their last menstrual period, and the same procedures should be followed as those 
described for STD clinics, including on-site pregnancy testing. If the test is positive, an on-site 
RPR should be performed and referral made for prenatal care. Patients should also be 
informed about the availability of family planning services and potential fetal damage caused 
by STD, cigarette smoking, alcohol, and drugs.
4.3 Pregnancy Testing Sites
All sites that provide pregnancy testing should be alerted to their responsibility for preventing 
congenital syphilis. If a woman has a positive pregnancy test, an RPR card test should be 
done immediately and on site. If the RPR is reactive, the same procedures should be followed 
as those described for STD clinics. Special attention should be paid to obtaining accurate 
addresses for use by the local STD intervention specialist. All sites that provide pregnancy 
testing should follow these procedures, including family planning clinics, school-based clinics, 
adolescent health clinics, hospital emergency rooms and outpatient clinics, and detention 
facilities.
4.4 Prenatal Care Sites
Women must often wait several weeks for their first prenatal appointment because of 
overcrowded schedules and delays in determining Medicaid eligibility. Since a delay may 
reduce the likelihood of successful treatment if syphilis is identified, efforts should be made to 
test women early in pregnancy, possibly during a visit for laboratory tests. If syphilis is 
diagnosed, treatment and counseling should be started before the regularly scheduled 
prenatal care visit.
4.5 Content o f Care
Prenatal care providers are responsible for ensuring that their pregnant patients are tested 
for syphilis and for coordinating their activities with those of the local STD program so that 
infected women will receive treatment promptly. Recommended activities for prenatal care 
providers include:
• Obtaining maternal blood for serologic testing at the first visit unless the results of a 
previous test during the current pregnancy are available. A second STS should be
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performed at the beginning of the third trimester (28 weeks).
• Providing each patient with a card identifying what test was performed, the date it was 
done, the result, what treatment (if any) was given, and the clinic’s name and telephone 
number.
• Maintaining a list, arranged by date of test and patient’s name, of the results of the STS. 
Entries should be maintained for 1 year after the pregnancy is terminated. Prenatal care 
providers are responsible for determining the serologic status of their patients. Providers 
either should obtain the specimen or should document that a nonreactive test was 
obtained earlier in the pregnancy. The patient-borne record of STS and reactive results will 
assist in this documentation.
• Identifying specimens from pregnant women by clearly labeling the laboratory slips 
“prenatal.” Reactive tests should be followed by the STD program as part of an ongoing 
surveillance activity (see section 2).
• “Flagging” the charts of clients whose serologic tests are reactive. Charts should remain 
flagged until the patient returns to the clinic. If the patient does not return or respond to 
routine notification, the local health department should be informed and referral services 
requested.
• Instructing pregnant patients who may not be involved in mutually monogamous rela­
tionships to insist that their sex partners use condoms during the full term of the 
pregnancy.
• Providing monthly quantitative nontreponemal serologic tests for the remainder of the 
current pregnancy of women who have been treated for early syphilis. Women who show a 
fourfold rise in titer should be retreated. Treated women who do not show a fourfold 
decrease in titer within 3 months should be retreated. After delivery, follow-up should be 
conducted as outlined for nonpregnant patients.
• Testing all patients for syphilis (RPR or VDRL) 1 month after they have completed 
treatment for any other STD diagnosed during pregnancy.
4.6 M onitoring Perform ance
The responsibility for monitoring the system of services for preventing congenital syphilis 
should rest with the state or local STD control program. Since personnel and priorities of the 
multiple programs involved in preventing congenital syphilis will change overtime, a tracking 
system to monitor performance and the changes in service delivery should be established 
and maintained.
5. Laboratory Tests
The usefulness of laboratory tests in the diagnosis of syphilis depends upon the selection of 
appropriate standard tests, listed below. The quality of such tests depends upon the use of 
quality reagents by well-trained personnel. Laboratories and the staff performing laboratory 
tests should be under strict quality control procedures and should participate regularly in 
performance evaluation and quality assurance programs.
Laboratory Tests for Syphilis
Standard Tests
• Antibody screening tests (nontreponemal)
— Rapid plasma reagin (RPR)
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— Venereal Disease Research Laboratory (VDRL)
— Unheated serum reagin (USR)
— Reagin screen test (RST)
• Antibody confirmatory tests (treponemal)
— Fluorescent treponemal antibody absorption (FTA-ABS)
— Fluorescent treponemal antibody absorption double staining 
(FTA-ABS DS)
— Microhemagglutination assay for antibody to T. pallidum (MHA-TP)
— Hemagglutination treponemal test for syphilis (HATTS)
— Bio-enzaBead Test (ELISA)
• Direct examination of lesion or tissue
— Darkfield microscopy
— Direct fluorescent antibody test for T. pallidum (DFA-TP)
— Silver stains (modified Steiner)
— Hematoxylin and eosin (H & E) stains
Experimental Tests
• FTA-ABS immunoglobulin (IgM)
• FTA-ABS 19S IgM
• IgM capture ELISA
6. Syphilis in Pregnancy
6.1 Maternal Serologies
tP^inn I f* h h°k ldbe Perf° rmed at the be9innin9 of prenatal care and at delivery. Intermediate 
P . e ©ginning of the third trimester (28 weeks) should also be routine for high-risk 
p a ions, eroreactive women must be evaluated promptly. This evaluation should include 
a is ory and physical examination, a quantitative nontreponemal test, and a confirmatory
Despite possible false-positive results in nontreponemal and treponemal tests, expectant 
mothers should be treated if 1) they have a reactive STS and 2) a prompt and thorough 
evaluation of the cause of the seroreactivity cannot be ensured. Special tests that include 
deoxyribonucleic acid (DNA) and Reiter absorptions for the fluorescent treponemal antibody 
(FTA) test eliminate most of the false-positive results. These tests can be performed by the 
Sexually Transmitted Diseases Laboratory Program, Center for Infectious Diseases, CDC, 
upon request from a reference laboratory. Delay in the presumptive treatment of a seroreactive 
pregnant woman, however, should never be allowed to exceed 4 weeks.
If a patient has a reactive nontreponemal test (e.g., VDRL), a nonreactive treponemal test 
(e.g., microhemagglutination assay for antibody to T. pallidum [MHA-TP]), and no clinical or 
epidemiologic evidence of syphilis, no treatment is necessary. Both the quantitative non­
treponemal test and the confirmatory test should be repeated within 4 weeks. If clinical or 
serologic evidence of syphilis is found, or if the diagnosis of syphilis cannot be excluded with 
reasonable certainty, the patient should be treated as outlined below (section 6.2.3). In 
pregnancy, nontreponemal test titers tend to increase nonspecifically. This tendency causes 
difficulty in distinguishing between antibodies due to reinfection and antibodies remaining 
from an earlier treated infection.
Vol. 37 / No. S-1 MMWR 9
Patients who have been adequately treated for syphilis in the past and who have documen­
tation of their treatment need not be retreated unless clinical, serologic, or epidemiologic 
evidence of reinfection exists, e.g., darkfield-positive lesions, a sustained (for >2 weeks) 
fourfold titer rise in a quantitative nontreponemal test, or a history of recent sexual exposure to 
a person with early infectious syphilis.
6.2 Treatment in Pregnancy
6.2.1 Data Limitations
In the past 20 years, no major clinical trials have involved the currently recommended 
treatments for syphilis in pregnant patients. Thus, public health personnel cannot determine 
whether a decrease in therapeutic efficacy has occurred with these treatment regimens. 
However, individual failures of treatment (i.e., the occurrence of congenital syphilis in an infant 
whose mother was treated) have been reported. Although denominator data would be neces­
sary for failure rates to be calculated, the reports nonetheless suggest the need to modify 
treatment strategies for pregnant women who have syphilis. For instance, the available data 
suggest that treatment with the currently recommended erythromycin regimen is associated 
with an unacceptably high failure rate.
The treatment efficacy with any regimen varies with the stage of maternal infection and with 
the stage of pregnancy. Available data indicate that the rate of treatment failure may be 
significantly higher among women with secondary syphilis and among women treated in the 
last trimester of pregnancy. The physiologic variables associated with pregnancy or placental 
transfer mechanisms may be quantitatively more important during the last trimester of 
pregnancy, and the organism load may be higher during the secondary stage of syphilis.
6.2.2 Treatment of Choice for Syphilis in Pregnancy
REGARDLESS OF THE STAGE OF PREGNANCY, PATIENTS 
WHO ARE NOT ALLERGIC TO PENICILLIN SHOULD BE 
TREATED WITH PENICILLIN ACCORDING TO THE DOSAGE 
SCHEDULES APPROPRIATE FOR THE STAGE OF SYPHILIS AS 
RECOMMENDED FOR NONPREGNANT PATIENTS.
Suspected failures of penicillin treatment should be completely evaluated and reported.
6.2.3 Penicillin-Allergic Patients
Penicillin may be given to pregnant women with syphilis even if they have a history of 
penicillin allergy provided 1) their skin-test reactions to the major and minor penicillin deter­
minants are negative or 2) their skin tests are positive but they are then desensitized to 
penicillin. Patients can be desensitized and then given standard dosages of this antibiotic.
Penicillin desensitization can be accomplished by giving the patient gradually increasing 
oral* or intravenous penicillin doses over a period of 3-4 hours until full tolerance occurs. The 
intravenous desensitizing route has an advantage in that the penicillin can be stopped 
immediately if an allergic reaction develops; reactions, however, occur more frequently during 
intravenous desensitization. Desensitization should be done in consultation with an expert 
and only in facilities where emergency procedures are available, such as in a hospital.
*One oral desensitizing regimen given to pregnant patients used penicillin V. The starting dose was 100 
units and was increased every 15 minutes. The final cumulative dose was 1,296,700 units given over a 
period of 3-4 hours. These patients were hospitalized and an intravenous line was established, but no 
premedications were used. A contingency plan, which was not needed, was to repeat the last dose or 
abandon the procedure if a serious reaction developed (N Engl J Med 1985;312:1229-32).
10
MMWR January 15, 1988
Tetracycline is not recommended for pregnant women because of potential adverse effects 
on the fetus. Erythromycin treatment of syphilis during pregnancy is generally discouraged, 
should be considered only for patients who have documented evidence of penicillin allergy 
(skin test or anaphylaxis history) and who are not candidates for penicillin desensitization. 
Clinicians choosing erythromycin treatment have a weighty responsibility for close clinical 
follow-up of both the mother and fetus to assess the possibilities of treatment failure.
6.2.4 Maternal Treatment Follow-up
• Pregnant women who have been treated for early syphilis should have monthly quan­
titative nontreponemal serologic tests for the remainder of their pregnancy.
• Women who show a fourfold rise in titer should be retreated.
• Treated women who do not show a fourfold decrease in titer in a 3-month period should 
be retreated.
• After delivery, follow-up is the same as for nonpregnant patients.
6.2.5 Needed Studies
Well-designed studies on the treatment of pregnant women who have syphilis are clearly 
needed. The more urgent topics include:
• the transplacental pharmacokinetics of penicillin and other antibiotics;
• treatment efficacy and a continuing analysis of treatment-failure cases with currently 
recommended regimens;
°* a treatment regimen consisting of benzathine penicillin G followed by 
for cunhii'H j mpiCI In anc* Pr°benecid, or high-dose amoxicillin/ampicillin and probenecid 
trimester dUnn9 pre9nancy’ esPecial|y for secondary syphilis encountered in the last
S eneCidrfaS ,an. aĉ unc* t0 current penicillin treatment regimens to augment their 
efficacy, particularly for secondary syphilis in late pregnancy; and
• the role of infection with HIV in cases of prenatal syphilis treatment failure.
7. Syphilis in the Fetus and Neonate
7.1 Diagnostic Evaluation
7.1.1 Neonatal Serologic Tests for Syphilis
Serum from the infant is preferred for both nontreponemal and confirmatory tests, since 
umbilical cord blood may produce false-positive results. After delivery and/or treatment, serial 
specimens are used to follow efficacy of treatment or degradation of transplacentally acquired 
maternal antibody.
When laboratory methods become generally available for fetal/neonatal specific immune 
globulin (IgM) treponemal determinations, serum will be the specimen of choice. Carefully 
controlled field trials will need to be conducted to provide guidance for their use in clinical 
practice.
7.1.2 Microscopic Evaluation
The placenta and the umbilical cord may serve as excellent sites for the collection o 
specimens that can be examined by darkfield microscopy, immunofluorescence, H & E stains,
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or silver stains. Specimens from the placenta and umbilical cord should be microscopically 
examined for those infants born to mothers with reactive serologic results, when no histories 
are available, or when the placenta is hydropic. Additionally, all neonatal lesions should be 
examined for treponemes.
Treponemes seen in lesion material or in autopsy or biopsy sections by silver stain or 
darkfield, although considered definitive, may be confused in endemic areas with the Borrelia 
of Lyme disease. Maternal nontreponemal serology may be used to differentiate Lyme 
disease from syphilis. The VDRL is uniformly nonreactive in Lyme disease.
An effort should be made to diagnose congenital syphilis in a stillborn whenever clinical 
findings or a maternal history suggests the possibility of untreated syphilis. Direct and 
histologic microscopic examinations of placenta, organs, and umbilical cord, as well as 
radiographic examinations of long bones, are helpful in postmortem diagnosis. The MHA-TP 
test can be used on the blood of a stillborn; blood can be obtained by direct cardiac puncture.
7.1.3 Radiography
All infants delivered of women with a reactive STS who were not treated before pregnancy or 
before 20 weeks’ gestation should be fully evaluated. The evaluation should include an 
examination of the long bones for osteochondritis, osteitis, and periostitis.
7.1.4 Cerebrospinal Fluid Analysis
Infants delivered of women with a reactive STS should have a cerebrospinal fluid (CSF) 
evaluation in any of the following circumstances:
• the infant shows any signs compatible with congenital syphilis
OR
• maternal therapy was inadequate, unknown, or it occurred late 20 weeks) in preg­
nancy
OR
• maternal therapy did not include penicillin
OR
• adequate follow-up cannot be ensured
Other living infants with a diagnosis of confirmed or compatible (see definitions in section 2) 
congenital syphilis should have a CSF examination before treatment to provide a baseline for 
follow-up examination. Although the importance of the CSF examination is debated, a quan­
titative VDRL CSF test can be meaningful if it is done in conjunction with tests for elevated total 
protein and lymphocyte count. The RPR card test should not be used for CSF evaluation.
Regardless of CSF results, however, all children with a diagnosis of confirmed or compatible 
congenital syphilis should be treated with a regimen effective for neurosyphilis.
7.2 Neonatal Treatment
Although no recent comprehensive and comparative data on the treatment of neonates are 
available, several case reports of apparent treatment failure in infants treated with benzathine 
penicillin have been published. Available data clearly identify an obligation to evaluate neo­
nates adequately to determine whether they have occult active infection. The most appropri­
ate approach to active infection requires the use of a 10-day regimen of crystalline or procaine 
penicillin rather than benzathine penicillin.
12 MMWR January 15, 1988
Recommended Regimens for 
Symptomatic or Asymptomatic Infants
Aqueous crystalline penicillin G 50,000 units/kg IM or IV daily in two divided doses for a 
minimum of 10 days
OR
Aqueous procaine penicillin G 50,000 units/kg IM daily for a minimum of 10 days.
For asymptomatic infants whose mothers were treated adequately with a penicillin regimen 
during pregnancy, treatment is not necessary if follow-up can be ensured.
For asymptomatic infants whose mothers were treated adequately with a penicillin regimen 
during pregnancy but whose follow-up cannot be ensured, many consultants recommend 
treatment with benzathine penicillin 50,000 units/kg IM in a single dose. Data on the efficacy of 
this regimen in congenital neurosyphilis are lacking; therefore, if neurosyphilis cannot be 
excluded, the 10-day regimens of aqueous crystalline penicillin or procaine penicillin are 
recommended. Only penicillin regimens are recommended for neonatal congenital syphilis.
7.3 Neonatal Follow-up
In accordance with the guidelines of the American Academy of Pediatrics, follow-up for all 
infants should be incorporated into routine newborn care at 1,2,4,6, and 12 months. Serologic 
tests should be performed until they become nonreactive. Patients with persistent, stable, low 
titers should be considered candidates for retreatment. Treated infants should be similarly 
followed, with a CSF examination at 6-month intervals until the examination becomes non­
reactive. A reactive CSF VDRL at 6 months is an indication for retreatment.
8. Long-term Follow-up and Retreatment
Penicillin dosages for congenital syphilis after the neonatal period remain the same as
ose recommended for neonatal congenital syphilis. For larger children, the total amount of 
penicillin given should not exceed the dosage used in adult syphilis of more than 1 year’s 
duration. After the neonatal period, the dosage of tetracycline for congenital syphilis in 
patients who are allergic to penicillin should be individualized, but these dosages need not 
exceed those used in adult syphilis of more than 1 year’s duration. Tetracycline should not be 
given to children <8 years of age.
A thorough developmental evaluation should be done during the third year of life (age 2) on 
all children treated in infancy who were symptomatic at birth or had active congenital infection.
All patients with early syphilis or congenital syphilis should be encouraged to return for 
repeat quantitative nontreponemal tests at least 3,6, and 12 months after treatment. In these 
patients, quantitative nontreponemal test titers will decline to nonreactive or low titer reactive 
within a year following successful treatment with penicillin. Serologic test results decline more 
slowly in patients treated for disease of longer duration. Patients with syphilis of more than
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follow-up serologic testing is particularly important for patients treated with antibiotics other 
than penicillin. Examination of CSF should be planned as part of the last follow-up visit after 
treatment with alternative antibiotics.
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All patients with neurosyphilis must be carefully monitored with periodic serologic testing, 
clinical evaluation at 6-month intervals, and repeat CSF examinations for at least 3 years.
The possibility of reinfection should always be considered when patients with early syphilis 
are being retreated. A CSF examination should be performed before retreatment unless 
reinfection and a diagnosis of early syphilis can be established.
Retreatment should be considered when:
• clinical signs or symptoms of syphilis persist or recur
OR
• a sustained fourfold increase occurs in the titer of a nontreponemal test
OR
• an initially high-titer nontreponemal test fails to decrease fourfold within a year
Patients should be retreated with the regimens recommended for syphilis of more than 
1 year’s duration.
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